FibroBiologics, Inc. Common Stock
FBLG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.21 | -0.81 | -16.93 |
| FCF Yield | -18.38% | -0.73% | -0.43% | -0.15% |
| EV / EBITDA | -5.90 | -59.00 | -217.32 | -599.48 |
| Quality | ||||
| ROIC | -103.38% | -296.30% | -126.62% | -15,780.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 0.39 | 0.79 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -75.25% | -69.60% | -188.37% | -20.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.47 | -1.20 | -0.57 |
| Interest Coverage | -686.85 | -60.47 | -6.83 | -394.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |